This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Jazz Pharmaceuticals (JAZZ) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Jazz Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Jazz Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Jazz (JAZZ) Down 7.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Jazz Pharmaceuticals (JAZZ) a Profitable Value Stock?
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) stock may be a good choice for value-oriented investors right now from multiple angles.
Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate
by Zacks Equity Research
Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.
Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019.
Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 13.45% and 5.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Bausch Health (BHC) in Q2 Earnings?
by Zacks Equity Research
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.
Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset
by Zacks Equity Research
Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.
ETF & Stock Winners of Longest US Economic Expansion
by Sanghamitra Saha
The U.S. economy has stepped into the 11th year of the expansion, exhibiting the longest expansion in history. These winning ETFs and stocks will rally further.
JAZZ or PCRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. PCRX: Which Stock Is the Better Value Option?
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.
Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Is Jazz (JAZZ) Down 7.3% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason
by Zacks Equity Research
Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason
Is Jazz (JAZZ) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.
5 Best PEG Stocks Suitable for GARP Investors
by Urmimala Biswas
While P/E alone only gives an idea of stocks that are trading at a discount, PEG, while adding the growth element to it, helps to identify stocks that have solid potential.
BioCryst Down Despite Hereditary Angioedema Study Meets Goal
by Zacks Equity Research
BioCryst's (BCRX) phase III study on BCX7353 for the prevention of hereditary angioedema attacks meets the primary endpoint for both doses (110mg/150 mg). Shares depreciate despite this upside.
JAZZ vs. PCRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
JAZZ vs. PCRX: Which Stock Is the Better Value Option?